Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2018

Aug 31, 2018

SELL
$10.99 - $44.21 $2,934 - $11,804
-267 Closed
0 $0
Q4 2017

Mar 28, 2018

SELL
$35.44 - $63.76 $3,827 - $6,886
-108 Reduced 28.8%
267 $0
Q3 2017

Nov 22, 2017

BUY
$53.83 - $67.75 $20,186 - $25,406
375
375 $0

Others Institutions Holding PRTA

About PROTHENA CORP PUBLIC LTD CO


  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $710M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Chicago Partners Investment Group LLC Portfolio

Follow Chicago Partners Investment Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Chicago Partners Investment Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Chicago Partners Investment Group LLC with notifications on news.